Hypoxia-inducible factors as key regulators of tumor inflammation

International Journal of Cancer

Volumn 132, Issue 12, 2013, Pages 2721-2729

  Mamlouk, Soulafa ^a   Wielockx, Ben ^a,b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

cancer inflammation; HIF; hypoxia

Indexed keywords

HYPOXIA INDUCIBLE FACTOR;

CELL HYPOXIA; HUMAN; INFLAMMATION; INFLAMMATORY CELL; MACROPHAGE; METASTASIS; MOLECULAR PATHOLOGY; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR INFLAMMATION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANIMALS; CELL HYPOXIA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; INFLAMMATION; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; ZINC FINGERS;

EID: 84876134353     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27901     Document Type: Review

References (145)

1. Sundelof LO,. Air and fire-Carl Wilhelm Scheele, Torbern Bergman, the Royal Society of Sciences and the discovery of oxygen in Uppsala in the year 1772. Adv Exp Med Biol 2009; 645: 1-6.
2. Gray LH, Conger AD, Ebert M, et al. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953; 26: 638-48.
3. Thomlinson RH, Gray LH,. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955; 9: 539-49.
4. Brown JM, Wilson WR,. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004; 4: 437-47.
5. Eberhard A, Kahlert S, Goede V, et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000; 60: 1388-93.
6. Morikawa S, Baluk P, Kaidoh T, et al. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002; 160: 985-1000.
7. McDonald DM, Baluk P,. Significance of blood vessel leakiness in cancer. Cancer Res 2002; 62: 5381-5.
8. Yuan J, Glazer PM,. Mutagenesis induced by the tumor microenvironment. Mutat Res 1998; 400: 439-46.
9. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379: 88-91.
10. Finger EC, Giaccia AJ,. Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev 2010; 29: 285-93.
11. Vaupel P, Mayer A,. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007; 26: 225-39.
12. Dewhirst MW, Cao Y, Moeller B,. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008; 8: 425-37.
13. Brown JM,. Tumor hypoxia in cancer therapy. Methods Enzymol 2007; 435: 297-321.
14. Bristow RG, Hill RP,. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008; 8: 180-92.
15. Tannock IF,. Conventional cancer therapy: promise broken or promise delayed? Lancet 1998; 351 (Suppl 2): SII9-SI16.
16. Minchinton AI, Tannock IF,. Drug penetration in solid tumours. Nat Rev Cancer 2006; 6: 583-92.
17. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005; 77: 18-24.
18. Bertout JA, Patel SA, Simon MC,. The impact of O2 availability on human cancer. Nat Rev Cancer 2008; 8: 967-75.
19. Warburg O,. On the origin of cancer cells. Science 1956; 123: 309-14.
20. Hanahan D, Folkman J,. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
21. Nelson DA, Tan T-T, Rabson AB, et al. Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes Dev 2004; 18: 2095-107.
22. Fang JS, Gillies RD, Gatenby RA,. Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression. Semin Cancer Biol 2008; 18: 330-7.
23. Semenza GL,. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012; 33: 207-14.
24. Majmundar AJ, Wong WJ, Simon MC,. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 2010; 40: 294-309.
25. Goldberg MA, Dunning SP, Bunn HF,. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 1988; 242: 1412-15.
26. Wang GL, Jiang BH, Rue EA, et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92: 5510-14.
27. Wang GL, Semenza GL,. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995; 270: 1230-7.
28. Semenza GL, Wang GL,. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992; 12: 5447-54.
29. Semenza GL,. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology (Bethesda) 2004; 19: 176-82.
30. Makino Y, Cao R, Svensson K, et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001; 414: 550-4.
31. Lando D, Peet DJ, Gorman JJ, et al. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 2002; 16: 1466-71.
32. Oehme F, Ellinghaus P, Kolkhof P, et al. Overexpression of PH-4, a novel putative proline 4-hydroxylase, modulates activity of hypoxia-inducible transcription factors. Biochem Biophys Res Commun 2002; 296: 343-9.
33. Berra E, Benizri E, Ginouves A, et al. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 2003; 22: 4082-90.
34. Takeda K, Ho VC, Takeda H, et al. Placental but not heart defects are associated with elevated hypoxia-inducible factor alpha levels in mice lacking prolyl hydroxylase domain protein 2. Mol Cell Biol 2006; 26: 8336-46.
35. Minamishima YA, Moslehi J, Bardeesy N, et al. Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood 2008; 111: 3236-44.
36. Takeda Y, Costa S, Delamarre E, et al. Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. Nature 2011; 479: 122-6.
37. Takeda K, Aguila HL, Parikh NS, et al. Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Blood 2008; 111: 3229-35.
38. Klotzsche-von Ameln A, Muschter A, Mamlouk S, et al. Inhibition of HIF prolyl hydroxylase-2 blocks tumor growth in mice through the antiproliferative activity of TGFbeta. Cancer Res 2011; 71: 3306-16.
39. Mazzone M, Dettori D, Leite de Oliveira, et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009; 136: 839-51.
40. Harris AL,. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47.
41. Keith B, Johnson RS, Simon MC,. HIF1a and HIF2a: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2012; 12: 9-22.
42. Stroefer Mf, Mareike, Jelkmann W, et al. Stabilisation and knockdown of HIF-two distinct ways comparably important in radiotherapy. Cell Physiol Biochem 2011; 28: 805-12.
43. Chan DA, Kawahara TLA, Sutphin PD, et al. Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell 2009; 15: 527-38.
44. Xue J, Li X, Jiao S, et al. Prolyl hydroxylase-3 is down-regulated in colorectal cancer cells and inhibits IKKbeta independent of hydroxylase activity. Gastroenterology 2010; 138: 606-15.
45. Su Y, Loos M, Giese N, et al. Prolyl hydroxylase-2 (PHD2) exerts tumor-suppressive activity in pancreatic cancer. Cancer 2012; 118: 960-72.
46. Tlsty TD, Coussens LM,. Tumor stroma and regulation of cancer development. Annu Rev Pathol 2006; 1: 119-50.
47. Schmidt A, Weber OF,. In memoriam of Rudolf virchow: a historical retrospective including aspects of inflammation, infection and neoplasia. Contrib Microbiol 2006; 13: 1-15.
48. Colotta F, Allavena P, Sica A, et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30: 1073-81.
49. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
50. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 2008; 454: 436-44.
51. Aggarwal BB, Shishodia S, Sandur SK, et al. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006; 72: 1605-21.
52. Terzic J, Grivennikov S, Karin E, et al. Inflammation and colon cancer. Gastroenterology 2010; 138: 2101-2114.e5.
53. Borrello MG, Alberti L, Fischer A, et al. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci USA 2005; 102: 14825-30.
54. Grivennikov SI, Greten FR, Karin M,. Immunity, inflammation, and cancer. Cell 2010; 140: 883-99.
55. Murdoch C, Giannoudis A, Lewis CE,. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004; 104: 2224-34.
56. Sica A, Saccani A, Bottazzi B, et al. Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinoma. J Immunol 2000; 164: 733-8.
57. Bosco MC, Reffo G, Puppo M, et al. Hypoxia inhibits the expression of the CCR5 chemokine receptor in macrophages. Cell Immunol 2004; 228: 1-7.
58. Dvorak HF,. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-9.
59. Fink T, Ebbesen P, Koppelhus U, et al. Natural killer cell-mediated basal and interferon-enhanced cytotoxicity against liver cancer cells is significantly impaired under in vivo oxygen conditions. Scand J Immunol 2003; 58: 607-12.
60. O'Sullivan C, Lewis CE,. Tumour-associated leucocytes: friends or foes in breast carcinoma. J Pathol 1994; 172: 229-35.
61. Lissbrant IF, Stattin P, Wikstrom P, et al. Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int J Oncol 2000; 17: 445-51.
62. Murdoch C, Muthana M, Coffelt SB, et al. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008; 8: 618-31.
63. Bellocq A, Antoine M, Flahault A, et al. Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome. Am J Pathol 1998; 152: 83-92.
64. Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450: 903-7.
65. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-8.
66. Scarlett UK, Rutkowski MR, Rauwerdink AM, et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med 2012; 209: 495-506.
67. Balkwill F, Charles KA, Mantovani A,. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7: 211-17.
68. Blay J, White TD, Hoskin DW,. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res 1997; 57: 2602-5.
69. Wei J, Wu A, Kong L-Y, et al. Hypoxia potentiates glioma-mediated immunosuppression. PLoS One 2011; 6: e16195.
70. Barsoum IB, Hamilton TK, Li X, Cotechini T, Miles EA, Siemens DR, Graham CH,. Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide. Cancer Res 2011; 71: 7433-41.
71. Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549-55.
72. Mantovani A, Sica A,. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010; 22: 231-7.
73. Lewis C, Murdoch C,. Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am J Pathol 2005; 167: 627-35.
74. Werno C, Menrad H, Weigert A, et al. Knockout of HIF-1alpha in tumor-associated macrophages enhances M2 polarization and attenuates their pro-angiogenic responses. Carcinogenesis 2010; 31: 1863-72.
75. DeNardo DG, Barreto JB, Andreu P, et al. CD4(+) T-cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009; 16: 91-102.
76. Doedens AL, Stockmann C, Rubinstein MP, et al. Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res 2010; 70: 7465-75.
77. Takeda N, O'Dea EL, Doedens A, et al. Differential activation and antagonistic function of HIF-alpha isoforms in macrophages are essential for NO homeostasis. Genes Dev 2010; 24: 491-501.
78. Bronte V, Serafini P, De Santo, et al. IL-4-induced arginase 1 suppresses alloreactive T-cells in tumor-bearing mice. J Immunol 2003; 170: 270-8.
79. Berchner-Pfannschmidt U, Yamac H, Trinidad B, et al. Nitric oxide modulates oxygen sensing by hypoxia-inducible factor 1-dependent induction of prolyl hydroxylase 2. J Biol Chem 2007; 282: 1788-96.
80. Ellies LG, Fishman M, Hardison J, et al. Mammary tumor latency is increased in mice lacking the inducible nitric oxide synthase. Int J Cancer 2003; 106: 1-7.
81. Niecknig H, Tug S, Reyes BD, et al. Role of reactive oxygen species in the regulation of HIF-1 by prolyl hydroxylase 2 under mild hypoxia. Free Radic Res 2012; 46: 705-17.
82. Brunelle JK, Bell EL, Quesada NM, et al. Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab 2005; 1: 409-14.
83. Guzy RD, Hoyos B, Robin E, et al. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab 2005; 1: 401-8.
84. Talks KL, Turley H, Gatter KC, et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000; 157: 411-21.
85. Hu CJ, Wang LY, Chodosh LA, et al. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 2003; 23: 9361-74.
86. Kawanaka T, Kubo A, Ikushima H, et al. Prognostic significance of HIF-2alpha expression on tumor infiltrating macrophages in patients with uterine cervical cancer undergoing radiotherapy. J Med Invest 2008; 55: 78-86.
87. Imtiyaz HZ, Williams EP, Hickey MM, et al. Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation. J Clin Invest 2010; 120: 2699-714.
88. Cramer T, Yamanishi Y, Clausen BE, et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 2003; 112: 645-57.
89. Peyssonnaux C, Datta V, Cramer T, et al. HIF-1alpha expression regulates the bactericidal capacity of phagocytes. J Clin Invest 2005; 115: 1806-15.
90. Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-11.
91. Schumacher K, Haensch W, Röefzaad C, Schlag PM,. Prognostic significance of activated CD8(+) T-cell infiltrations within esophageal carcinomas. Cancer Res 2001; 61: 3932-6.
92. Rabinovich GA, Gabrilovich D, Sotomayor EM,. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25: 267-96.
93. Willimsky G, Blankenstein T,. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 2005; 437: 141-6.
94. Thornton RD, Lane P, Borghaei RC, et al. Interleukin 1 induces hypoxia-inducible factor 1 in human gingival and synovial fibroblasts. Biochem J 2000; 350 (Part 1): 307-12.
95. Nakamura H, Makino Y, Okamoto K, et al. TCR engagement increases hypoxia-inducible factor-1 alpha protein synthesis via rapamycin-sensitive pathway under hypoxic conditions in human peripheral T-cells. J Immunol 2005; 174: 7592-9.
96. Lukashev D, Caldwell C, Ohta A, et al. Differential regulation of two alternatively spliced isoforms of hypoxia-inducible factor-1 alpha in activated T lymphocytes. J Biol Chem 2001; 276: 48754-63.
97. Wenger RH, Rolfs A, Kvietikova I, et al. The mouse gene for hypoxia-inducible factor-1alpha-genomic organization, expression and characterization of an alternative first exon and 5′ flanking sequence. Eur J Biochem/FEBS 1997; 246: 155-65.
98. Lukashev D, Klebanov B, Kojima H, et al. Cutting edge: hypoxia-inducible factor 1alpha and its activation-inducible short isoform I.1 negatively regulate functions of CD4+ and CD8+ T lymphocytes. J Immunol 2006; 177: 4962-5.
99. Lukashev D, Ohta A, Sitkovsky M,. Hypoxia-dependent anti-inflammatory pathways in protection of cancerous tissues. Cancer Metastasis Rev 2007; 26: 273-9.
100. Kurobe H, Urata M, Ueno M, et al. Role of hypoxia-inducible factor 1alpha in T-cells as a negative regulator in development of vascular remodeling. Arterioscler Thromb Vasc Biol 2010; 30: 210-17.
101. Strauss L, Bergmann C, Szczepanski M, et al. A unique subset of CD4+CD25highFoxp3+ T-cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 2007; 13: 4345-54.
102. Facciabene A, Peng X, Hagemann IS, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011; 475: 226-30.
103. Dang EV, Barbi J, Yang H-Y, et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell 2011; 146: 772-84.
104. Youn J-I, Gabrilovich DI,. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 2010; 40: 2969-75.
105. Pastula A, Marcinkiewicz J,. Myeloid-derived suppressor cells: a double-edged sword? Int J Exp Pathol 2011; 92: 73-8.
106. Gabrilovich DI, Nagaraj S,. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-74.
107. Sica A, Bronte V,. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007; 117: 1155-66.
108. Diaz-Montero CM, Salem ML, Nishimura MI, et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009; 58: 49-59.
109. Corzo CA, Condamine T, Lu L, et al. HIF-1a regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 2010; 207: 2439-53.
110. Jantsch J, Chakravortty D, Turza N, et al. Hypoxia and hypoxia-inducible factor-1 alpha modulate lipopolysaccharide-induced dendritic cell activation and function. J Immunol 2008; 180: 4697-705.
111. Blengio F, Raggi F, Pierobon D, Cappello P, Eva A, Giovarelli M, Varesio L, Bosco MC,. The hypoxic environment reprograms the cytokine/chemokine expression profile of human mature dendritic cells. Immunobiology 2012.
112. Sumbayev VV, Yasinska I, Oniku AE, et al. Involvement of hypoxia-inducible factor-1 in the inflammatory responses of human LAD2 masT-cells and basophils. PLoS One 2012; 7: e34259.
113. Walczak-Drzewiecka A, Ratajewski M, Wagner W, et al. HIF-1alpha is up-regulated in activated masT-cells by a process that involves calcineurin and NFAT. J Immunol 2008; 181: 1665-72.
114. Palucka K, Banchereau J,. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12: 265-77.
115. Walmsley SR, Print C, Farahi N, et al. Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NF-kappaB activity. J Exp Med 2005; 201: 105-15.
116. Cummins EP, Berra E, Comerford KM, et al. Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci USA 2006; 103: 18154-9.
117. Lewis CE, Pollard JW,. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006; 66: 605-12.
118. White JR, Harris RA, Lee SR, et al. Genetic amplification of the transcriptional response to hypoxia as a novel means of identifying regulators of angiogenesis. Genomics 2004; 83: 1-8.
119. Pollard JW,. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4: 71-8.
120. Qian B-Z, Pollard JW,. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141: 39-51.
121. Lin EY, Li J-F, Gnatovskiy L, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 2006; 66: 11238-46.
122. Stockmann C, Doedens A, Weidemann A, et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 2008; 456: 814-18.
123. Roda JM, Sumner LA, Evans R, et al. Hypoxia-inducible factor-2a regulates GM-CSF-derived soluble vascular endothelial growth factor receptor 1 production from macrophages and inhibits tumor growth and angiogenesis. J Immunol 2011; 187: 1970-6.
124. Leek RD, Talks KL, Pezzella F, et al. Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer. Cancer Res 2002; 62: 1326-9.
125. Petrella BL, Lohi J, Brinckerhoff CE,. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma. Oncogene 2005; 24: 1043-52.
126. Burke B, Giannoudis A, Corke KP, et al. Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. Am J Pathol 2003; 163: 1233-43.
127. Huang S, Van Arsdall M, Tedjarati S, et al. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst 2002; 94: 1134-42.
128. Venneri MA, De Palma, Michele, et al. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 2007; 109: 5276-85.
129. Murdoch C, Tazzyman S, Webster S, et al. Expression of Tie-2 by human monocytes and their responses to angiopoietin-2. J Immunol 2007; 178: 7405-11.
130. Klotzsche-von Ameln A, Muschter A, Heimesaat MM, et al. HIF prolyl hydroxylase-2 inhibition diminishes tumor growth through matrix metalloproteinase-induced TGFbeta activation. Cancer Biol Ther 2012; 13: 216-23.
131. Kaplan RN, Psaila B, Lyden D,. Bone marrow cells in the 'pre-metastatic niche': within bone and beyond. Cancer Metastasis Rev 2006; 25: 521-9.
132. Qian B, Deng Y, Im JH, et al. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One 2009; 4: e6562.
133. Tang N, Wang L, Esko J, et al. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 2004; 6: 485-95.
134. Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003; 3: 347-61.
135. Canning MT, Postovit LM, Clarke SH, et al. Oxygen-mediated regulation of gelatinase and tissue inhibitor of metalloproteinases-1 expression by invasive cells. Exp Cell Res 2001; 267: 88-94.
136. Wong CC-L, Gilkes DM, Zhang H, et al. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc Natl Acad Sci USA 2011; 108: 16369-74.
137. Burke B, Tang N, Corke KP, et al. Expression of HIF-1alpha by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J Pathol 2002; 196: 204-12.
138. Miyoshi A, Kitajima Y, Ide T, et al. Hypoxia accelerates cancer invasion of hepatoma cells by upregulating MMP expression in an HIF-1alpha-independent manner. Int J Oncol 2006; 29: 1533-9.
139. Grimshaw MJ, Wilson JL, Balkwill FR,. Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumors. Eur J Immunol 2002; 32: 2393-400.
140. Zhu S, Zhou Y, Wang L, et al. Transcriptional upregulation of MT2-MMP in response to hypoxia is promoted by HIF-1 in cancer cells. Mol Carcinog 2011; 50: 770-80.
141. Yang S, Kim J, Ryu J-H, et al. Hypoxia-inducible factor-2alpha is a catabolic regulator of osteoarthritic cartilage destruction. Nat Med 2010; 16: 687-93.
142. Nizet V, Johnson RS,. Interdependence of hypoxic and innate immune responses. Nat Rev Immunol 2009; 9: 609-17.
143. Leek RD, Harris AL,. Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia 2002; 7: 177-89.
144. Biswas SK, Mantovani A,. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010; 11: 889-96.
145. Allavena P, Mantovani A,. Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol 2012; 167: 195-205.